Brachytherapy is a form of radiation treatment aimed at a short distance from the site of the tumor. In this type of treatment, radioactive seeds are placed within the cancerous tissue to attack it directly without harming the surrounding tissues. This treatment is helpful particularly for patients with gynecological, breast, or prostate cancers.
High-Dose Rate (HDR) and Low-Dose Rate (LDR) brachytherapy are two forms of brachytherapy with varying levels of radiation strength and application time. Cases of pulmonary and head and neck cancer are treated with HDR as it is cost-effective than its counterpart. Safety guidelines for radiation doses by the National Investigation Agency (NIA) and the U.S. Environmental Protection Agency (EPA) can minimize health risks, thereby encouraging the adoption of this treatment among patients.
Minimize Hospital Stay
Major applications of brachytherapy are breast cancer, prostate cancer, gynecological cancer, and others. The breast cancer segment is anticipated to expand at a CAGR exceeding 5% over the forecast years (from 2018 to 2025) owing to high disease incidence. According to the American Cancer Society, breast cancer is one of the most common types of cancer in the U.S. The prostate cancer segment is anticipated to expand at a decent CAGR due to the use of brachytherapy in most developed countries for the disease treatment.
According to the American Cancer Society, there were nearly 161,370 cases of prostate cancer in 2017 due to unhealthy lifestyles and increased cases of obesity. Companies in this filed are focusing on R&D to offer more effective treatments such as providing real-time solutions to reduce hospital stay. An instance of this includes the Real-time Prostate Solutions by Elekta AB that completes the session in a single day without harming any organs of the patient.
Market Insights
The global brachytherapy market is projected to reach at USD 486.9 million by 2025, according to a report by Grand View Research, Inc. It is expected to exhibit a CAGR of 4.06% over the forecast period. Highly unmet clinical needs in several parts of the world, growing geriatric population base, and sedentary lifestyles are the major growth-driving factors for the market.
Moreover, preference for minimally invasive surgeries and presence of favorable medical reimbursement schemes are predicted to drive the market. Emerging economies, such as China, India, and Brazil, are expected to open up new avenues for market growth. Key companies in the industry include IsoRay Medical, Inc.; Elekta AB; Eckert & Ziegler BEBIG S.A.; and Theragenics Corporation.
In-Depth Research Report On Brachytherapy Market:
https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market
No comments:
Post a Comment